Reduced Interleukin-17 and Transforming Growth Factor Beta Levels in Peripheral Blood as Indicators for Following the Course of Bladder Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vigorous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, including autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-β) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 bladder cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-β were measured by the enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p＜0.0001) and TGF-β (p＜0.0001) were significantly lower in the patients compared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics between control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-related cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.
Abstract
Interleukin (IL) 17 is produced by T-helper (Th) 17 with a vigorous effect on cells of the immune system playing important roles in pathogenesis of immune-mediated diseases, including autoimmune disorders and cancers. Therefore, the aim of current study was to determine the serum levels of IL-6, IL-17, and transforming growth factor beta (TGF-β) in Iranian bladder cancer patients, and to correlate them with disease status. Blood samples were collected from 40 bladder cancer patients and 38 healthy individuals with no history of malignancies or autoimmune disorders. The serum levels of IL-6, IL-17, and TGF-β were measured by the enzyme-linked immunosorbent assay (ELISA). The results showed that the levels of IL-17 (p＜0.0001) and TGF-β (p＜0.0001) were significantly lower in the patients compared to the controls. No significant differences in the level of serum IL-6 (p=0.16) was observed between the patients and controls. In addition, demographic characteristics between control and patients groups were not significantly different. As most of the cases studied in this investigation were in stage I and II, it is concluded that reduced Th17-related cytokines can be used as indicators for following the course and clinical stages of bladder carcinoma progress and immune response to cancer.
참고문헌 (37)
- Mosmann, T. R., "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins", J. Immunol, 175, pp.5~14 (2005)
- Park, H., "A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17", Nat. Immunol, 6, pp.1133~1141 (2005)
- Annunziato, "Phenotypic and functional features of human Th17 cells", J. Exp. Med, 204, pp.1849~1861 (2007)
- Peck, A., "Breaking old paradigms: Th17 cells in autoimmune arthritis", Clin. Immunol, 132, pp.295~304 (2009)
- Sfanos, K. S, "Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing", Clin. Cancer Res, 14, pp.3254~3261 (2008)
- Kryczek, I., "Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment", J. Immunol, 178, pp.6730~6733 (2007)
- Dong, C, "TH17 cells in development: an updated view of their molecular identity and genetic programming", Nat. Rev. Immunol, 8, pp.337~348 (2008)
- Nam, J. S., "Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17", Cancer Res, 68, pp.3915~3923 (2008)
- Shime, H, "Tumor-secreted lactic acid promotes IL-23", IL-17 proinflammatory pathway, 2008, pp.180, 7175~7183
- Passos, S. T., "IL-6 promotes NK cell production of IL-17 during toxoplasmosis", J. Immunol, 184, pp.1776~1783 (2010)
- Mucida, D., "TGFbeta and retinoic acid intersect in immune-regulation", Cell Adh. Migr, 1, pp.142~144 (2007)
- Bettelli, E., "Induction and effector functions of T(H)17 cells", Nature, 453, pp.1051~1057 (2008)
- Fossiez, F., "T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines", J. Exp. Med, 183, pp.2593~2603 (1996)
- Murugaiyan, G., "Protumor vs antitumor functions of IL-17", J. Immunol, 183, pp.4169~4175 (2009)
- Zhang, "The prevalence of Th17 cells in patients with gastric cancer", Biochem. Biophys. Res. Commun, 374, pp.533~537 (2008)
- Honorati, M. C., "Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts1", Osteoarthritis Cartilage, 14, pp.345~352 (2006)
- Jeon, S. H, "Mechanisms underlying TGF-ß1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis", J. Leukoc. Biol, 81, pp.557~566 (2007)
- Wang, L., "IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway", J. Exp. Med, 206, pp.1457~1464 (2009)
- Radosavljevic, G., "Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma", Neoplasma, 57, pp.135~144 (2010)
- Jovanovic, D. V., "IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages", J. Immunol, 160, pp.3513~3521 (1998)
- Muranski, P., "Tumor-specific Th17-polarized cells eradicate large established melanoma", Blood, 112, pp.362~373 (2008)
- Ankathatti Munegowda M, "Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity", Cancer Immunol. Immunother, 60, pp.1473~1484 (2011)
- Kolahdoozan S, "Five common cancers in Iran", Arch. Iran. Med, 13, pp.143~146 (2010)
- Zhang, J. P, "Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients", J. Hepatol, 50, pp.980~989 (2009)
- Zhang, B., "The prevalence of Th17 cells in patients with gastric cancer", Biochem. Biophys. Res. Commun, 374, pp.533~537 (2008)
- Zhu, X., "IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines", Breast Cancer Res, 10, pp.R95~ (2008)
- Kato, T, "Expression of IL-17 mRNA in ovarian cancer", Biochem. Biophys. Res. Commun, 282, pp.735~738 (2001)
- Chi, L. J., "Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma", Clin. Exp. Immunol, 161, pp.480~489 (2010)
- Lee, J. J, "Increased prevalence of interleukin-17-producing CD4＋ tumor infiltrating lymphocytes in human oral squamous cell carcinoma", Head Neck, 33, pp.1301~1308 (2011)
- Kwon, K. A., "Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer", BMC Cancer, 10, pp.203~ (2010)
- Ravishankaran, P., "Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients", World J. Surg. Oncol, 9, pp.18~ (2011)
- Chen, M. F, "IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer", PLoS One, 8, pp.e61901~ (2013)
- Yang, L, "Expression of Th17 cells in breast cancer tissue and its association with clinical parameters", Cell Biochem. Biophys, 62, pp.153~159 (2012)
- Weaver, C. T, "Interplay between the TH17 and TReg cell lineages: a (co-) evolutionary perspective", Nat. Rev. Immunol, 9, pp.883~889 (2009)
- Khatami, M., "Inflammation, aging, and cancer: tumoricidal versus tumorigenesis of immunity: a common denominator mapping chronic diseases", Cell Biochem. Biophys, 55, pp.55~79 (2009)
- Erdman, S. E., "Roles for inflammation and regulatory T cells in colon cancer", Toxicol. Pathol, 38, pp.76~87 (2010)
- Connolly, E. C, "Complexities of TGF-beta Targeted Cancer Therapy", Int. J. Biol. Sci, 8, pp.964~978 (2012)